Concord Biotech Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: September 6, 2025, 12:20 am

Quick Insight

Concord Biotech Ltd, with an intrinsic value of 1,706 and a market cap of 17,849 Cr., is trading at a P/E ratio of 50.0, reflecting investor confidence in its growth potential. The company's robust ROE of 21.4% and ROCE of 28.4% indicate efficient capital utilization. With an OPM of 30%, Concord Biotech demonstrates strong operational efficiency. The company's healthy net profit of 373 Cr. and substantial reserves of 1,802 Cr. position it well for future expansion. Additionally, a conservative level of borrowings at ₹3 Cr. and a high ICR of 1040.58x underscore its financial stability. Overall, Concord Biotech appears well-positioned for sustained growth and value creation.

Competitors of Concord Biotech Ltd

All Competitor Stocks of Concord Biotech Ltd

Quarterly Result

Last Updated: August 19, 2025, 8:50 pm

Below is a detailed analysis of the quarterly data for Concord Biotech Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 204.00 Cr.. The value appears to be declining and may need further review. It has decreased from 430.00 Cr. (Mar 2025) to 204.00 Cr., marking a decrease of 226.00 Cr..
• For Expenses, as of Jun 2025, the value is 143.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 239.00 Cr. (Mar 2025) to 143.00 Cr., marking a decrease of 96.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 61.00 Cr.. The value appears to be declining and may need further review. It has decreased from 190.00 Cr. (Mar 2025) to 61.00 Cr., marking a decrease of 129.00 Cr..
• For OPM %, as of Jun 2025, the value is 30.00%. The value appears to be declining and may need further review. It has decreased from 44.00% (Mar 2025) to 30.00%, marking a decrease of 14.00%.
• For Other Income, as of Jun 2025, the value is 14.00 Cr.. The value appears strong and on an upward trend. It has increased from 9.00 Cr. (Mar 2025) to 14.00 Cr., marking an increase of 5.00 Cr..
• For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
• For Depreciation, as of Jun 2025, the value is 18.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15.00 Cr. (Mar 2025) to 18.00 Cr., marking an increase of 3.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 57.00 Cr.. The value appears to be declining and may need further review. It has decreased from 185.00 Cr. (Mar 2025) to 57.00 Cr., marking a decrease of 128.00 Cr..
• For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 23.00% (Mar 2025) to 26.00%, marking an increase of 3.00%.
• For Net Profit, as of Jun 2025, the value is 43.00 Cr.. The value appears to be declining and may need further review. It has decreased from 142.00 Cr. (Mar 2025) to 43.00 Cr., marking a decrease of 99.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 4.07. The value appears to be declining and may need further review. It has decreased from 13.57 (Mar 2025) to 4.07, marking a decrease of 9.50.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 2:07 pm

Growth

Last Updated: September 5, 2025, 3:01 pm

Balance Sheet

Last Updated: July 25, 2025, 1:32 pm

Below is a detailed analysis of the balance sheet data for Concord Biotech Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 10.00 Cr..
• For Reserves, as of Mar 2025, the value is 1,802.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,515.00 Cr. (Mar 2024) to 1,802.00 Cr., marking an increase of 287.00 Cr..
• For Borrowings, as of Mar 2025, the value is 3.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 10.00 Cr. (Mar 2024) to 3.00 Cr., marking a decrease of 7.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 219.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 164.00 Cr. (Mar 2024) to 219.00 Cr., marking an increase of 55.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 2,034.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,699.00 Cr. (Mar 2024) to 2,034.00 Cr., marking an increase of 335.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 795.00 Cr.. The value appears strong and on an upward trend. It has increased from 575.00 Cr. (Mar 2024) to 795.00 Cr., marking an increase of 220.00 Cr..
• For CWIP, as of Mar 2025, the value is 50.00 Cr.. The value appears to be declining and may need further review. It has decreased from 211.00 Cr. (Mar 2024) to 50.00 Cr., marking a decrease of 161.00 Cr..
• For Investments, as of Mar 2025, the value is 335.00 Cr.. The value appears strong and on an upward trend. It has increased from 244.00 Cr. (Mar 2024) to 335.00 Cr., marking an increase of 91.00 Cr..
• For Other Assets, as of Mar 2025, the value is 854.00 Cr.. The value appears strong and on an upward trend. It has increased from 668.00 Cr. (Mar 2024) to 854.00 Cr., marking an increase of 186.00 Cr..
• For Total Assets, as of Mar 2025, the value is 2,034.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,699.00 Cr. (Mar 2024) to 2,034.00 Cr., marking an increase of 335.00 Cr..

Notably, the Reserves (1,802.00 Cr.) exceed the Borrowings (3.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

No data available for the No. of Shareholders chart.

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Concord Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 35.52. This value is within the healthy range. It has increased from 29.45 (Mar 24) to 35.52, marking an increase of 6.07.
• For Diluted EPS (Rs.), as of Mar 25, the value is 35.52. This value is within the healthy range. It has increased from 29.45 (Mar 24) to 35.52, marking an increase of 6.07.
• For Cash EPS (Rs.), as of Mar 25, the value is 40.85. This value is within the healthy range. It has increased from 34.25 (Mar 24) to 40.85, marking an increase of 6.60.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 173.27. It has increased from 145.93 (Mar 24) to 173.27, marking an increase of 27.34.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 173.27. It has increased from 145.93 (Mar 24) to 173.27, marking an increase of 27.34.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 114.71. It has increased from 97.21 (Mar 24) to 114.71, marking an increase of 17.50.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 52.65. This value is within the healthy range. It has increased from 44.48 (Mar 24) to 52.65, marking an increase of 8.17.
• For PBIT / Share (Rs.), as of Mar 25, the value is 47.45. This value is within the healthy range. It has increased from 39.36 (Mar 24) to 47.45, marking an increase of 8.09.
• For PBT / Share (Rs.), as of Mar 25, the value is 47.40. This value is within the healthy range. It has increased from 39.11 (Mar 24) to 47.40, marking an increase of 8.29.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 35.65. This value is within the healthy range. It has increased from 29.13 (Mar 24) to 35.65, marking an increase of 6.52.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 35.52. This value is within the healthy range. It has increased from 29.45 (Mar 24) to 35.52, marking an increase of 6.07.
• For PBDIT Margin (%), as of Mar 25, the value is 45.89. This value is within the healthy range. It has increased from 45.75 (Mar 24) to 45.89, marking an increase of 0.14.
• For PBIT Margin (%), as of Mar 25, the value is 41.36. This value exceeds the healthy maximum of 20. It has increased from 40.48 (Mar 24) to 41.36, marking an increase of 0.88.
• For PBT Margin (%), as of Mar 25, the value is 41.31. This value is within the healthy range. It has increased from 40.23 (Mar 24) to 41.31, marking an increase of 1.08.
• For Net Profit Margin (%), as of Mar 25, the value is 31.07. This value exceeds the healthy maximum of 10. It has increased from 29.96 (Mar 24) to 31.07, marking an increase of 1.11.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 30.96. This value exceeds the healthy maximum of 20. It has increased from 30.29 (Mar 24) to 30.96, marking an increase of 0.67.
• For Return on Networth / Equity (%), as of Mar 25, the value is 20.50. This value is within the healthy range. It has increased from 20.18 (Mar 24) to 20.50, marking an increase of 0.32.
• For Return on Capital Employeed (%), as of Mar 25, the value is 26.82. This value is within the healthy range. It has increased from 26.41 (Mar 24) to 26.82, marking an increase of 0.41.
• For Return On Assets (%), as of Mar 25, the value is 18.26. This value is within the healthy range. It has increased from 18.11 (Mar 24) to 18.26, marking an increase of 0.15.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.64. It has increased from 0.63 (Mar 24) to 0.64, marking an increase of 0.01.
• For Current Ratio (X), as of Mar 25, the value is 6.17. This value exceeds the healthy maximum of 3. It has decreased from 6.30 (Mar 24) to 6.17, marking a decrease of 0.13.
• For Quick Ratio (X), as of Mar 25, the value is 4.87. This value exceeds the healthy maximum of 2. It has increased from 4.84 (Mar 24) to 4.87, marking an increase of 0.03.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.18. This value is below the healthy minimum of 4. It has increased from 0.87 (Mar 24) to 1.18, marking an increase of 0.31.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 23.19 (Mar 24) to 0.00, marking a decrease of 23.19.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 19.75 (Mar 24) to 0.00, marking a decrease of 19.75.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 76.81 (Mar 24) to 0.00, marking a decrease of 76.81.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 80.25 (Mar 24) to 0.00, marking a decrease of 80.25.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 1,040.58. This value is within the healthy range. It has increased from 182.35 (Mar 24) to 1,040.58, marking an increase of 858.23.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 705.64. This value is within the healthy range. It has increased from 120.41 (Mar 24) to 705.64, marking an increase of 585.23.
• For Enterprise Value (Cr.), as of Mar 25, the value is 17,536.50. It has increased from 15,881.24 (Mar 24) to 17,536.50, marking an increase of 1,655.26.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 14.61. This value exceeds the healthy maximum of 3. It has decreased from 15.62 (Mar 24) to 14.61, marking a decrease of 1.01.
• For EV / EBITDA (X), as of Mar 25, the value is 31.84. This value exceeds the healthy maximum of 15. It has decreased from 34.13 (Mar 24) to 31.84, marking a decrease of 2.29.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 14.61. This value exceeds the healthy maximum of 3. It has decreased from 15.66 (Mar 24) to 14.61, marking a decrease of 1.05.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 76.80 (Mar 24) to 0.00, marking a decrease of 76.80.
• For Price / BV (X), as of Mar 25, the value is 9.67. This value exceeds the healthy maximum of 3. It has decreased from 10.43 (Mar 24) to 9.67, marking a decrease of 0.76.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 14.61. This value exceeds the healthy maximum of 3. It has decreased from 15.66 (Mar 24) to 14.61, marking a decrease of 1.05.
• For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness